
1. j med chem. 2017 jun 22;60(12):4780-4804. doi: 10.1021/acs.jmedchem.6b01595. epub
2017 mar 15.

lysine deacetylase inhibitors parasites: past, present, future
perspectives.

hailu gs(1), robaa d(2), forgione m(1)(3), sippl w(2), rotili d(1), mai a(1)(4).

author information: 
(1)dipartimento di chimica e tecnologie del farmaco "sapienza" università di roma
, 00185 rome, italy.
(2)institute pharmacy, martin-luther-universitat halle-wittenberg , halle,
germany.
(3)center life nano science@sapienza, italian institute technology , viale
regina elena 291, 00161 rome, italy.
(4)istituto pasteur, fondazione cenci-bolognetti, "sapienza" università di roma ,
00185 rome, italy.

current therapies human parasite infections rely drugs, of
which severe side effects, helpfulness seriously
compromised drug resistance problem. globally, pushing discovery
research antiparasitic drugs toward new agents endowed new mechanisms 
action. using "drug repurposing" strategy, histone deacetylase inhibitors
(hdaci), presently clinically approved cancer use, under
investigation various parasite infections. parasitic zn2+- and
nad+-dependent hdacs play crucial roles modulation parasite gene
expression many pro-survival several parasites various 
conditions, emerging novel potential antiparasitic targets. 
perspective summarizes state knowledge hdaci (both class i/ii hdaci and
sirtuin inhibitors) targeted main human parasitic diseases
(schistosomiasis, malaria, trypanosomiasis, leishmaniasis, toxoplasmosis) and
provides visions main issues challenge development as
antiparasitic agents.

doi: 10.1021/acs.jmedchem.6b01595 
pmid: 28241112  [indexed medline]

